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Abstract: Peripheral arterial disease (PAD) is a condition typiﬁ  ed by decreased arterial blood 
ﬂ  ow in the non-coronary branches of the aorta as a result of chronic atherosclerosis. Despite 
the higher prevalence of PAD compared with other cardiovascular entities such as myocardial 
infarction and stroke, far less import is given to its diagnosis and treatment. In this review, we 
highlight principal diagnostic and therapeutic considerations in the management of PAD and 
its complications. We particularly emphasize the role of clopidogrel in the reduction of risks 
associated with PAD. 
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Introduction
For many years, peripheral arterial disease (PAD) has been identiﬁ  ed as and limited 
to occlusive arterial disease in the lower extremities. The more accurate and preferred 
deﬁ  nition of PAD is atherosclerotic stenosis, occlusion, or aneurysmal disease of the 
aorta and its non-coronary branches (Hirsch et al 1996). PAD in the vast majority of 
patients is asymptomatic. Symptomatic manifestations vary depending on the location 
and extent of the disease, the acuity or chronicity of the disease, and whether it leads 
to stenosis or aneurysms of the arteries afﬂ  icted. 
In the lower extremities, PAD can manifest as intermittent claudication, character-
ized as pain or fatigue in the lower extremities during ambulation. In its most severe 
form, patients may suffer from rest leg pain, non-healing leg ulcers, or frank gangrene 
leading to limb amputation (Cavendish and Safani 2004). In the aorta, atherosclerosis 
leads to stenoses of the renal, mesenteric and common iliac arteries. The atherosclerosis 
encroaches on the ostia of theses arteries and causes subsequent renal insufﬁ  ciency and 
hypertension, mesenteric ischemia, or severe claudication. Aneurysmal formation can 
develop in many arteries secondary to atherosclerosis. The aorta, iliac, and popliteal 
arteries are more commonly affected. Atherosclerosis also affects the brachiocephalic 
arteries and is a signiﬁ  cant cause of stroke when plaque rupture occurs in the carotid 
or vertebral arteries. 
PAD is thought to affect up to 12 million Americans. Numerous epidemiologi-
cal studies have shown that the prevalence of PAD increases with age (Criqui et al 
1985; Newman et al 1993; Aronow et al 2002). Symptomatic PAD affects up to 30% 
of elderly patients as shown in one nursing home cohort (Aronow et al 2002). The 
need for increasing awareness of diagnosis and treatment of PAD is underscored by 
statistics showing that patients with PAD have a ﬁ  ve-fold increased risk of dying 
from an atherothrombotic cardiovascular event (Criqui et al 1992). Additionally, 
atherothrombosis, in its varying clinical presentations, is the leading cause of mortality 
worldwide (Hirsch et al 1996; Lopez and Murray 1998; Fuster et al 2005). Therefore, 
diagnosing PAD and prevention of atherothrombotic events with aggressive risk factor Vascular Health and Risk Management 2007:3(3)  290
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modiﬁ  cation and antiplatelet therapy will have a great impact 
on the survival of patients with PAD. 
Awareness and treatment of PAD has been notably poor 
over the past two decades. Enthusiasm has increased particu-
larly in light of recent endovascular advances in the treatment 
of peripheral arterial stenoses. As medical device companies 
have developed balloons, stents, cryoablation, and atherec-
tomy instruments, a surge to screen, diagnose, and treat these 
patients has begun. Board certiﬁ  cation in vascular medicine is 
currently available through the American Board of Vascular 
Medicine, which offers certiﬁ  cation examinations in general 
vascular medicine and endovascular therapy. The publication 
of the American College of Cardiology (ACC) and American 
Heart Association (AHA) Guidelines on the Management of 
Patients with PAD further advances awareness and education 
with appropriate recommendations for the evaluation and 
treatment of patients with PAD. (Hirsch et al 1996) These 
guidelines are speciﬁ  c for lower extremity arterial occlusive 
disease, renal artery stenosis, mesenteric ischemia, and aneu-
rysmal disease of abdominal aorta, its branch vessels, and the 
lower extremities. The guidelines not only outline appropriate 
indications for endovascular or surgical revascularization of 
stenosed arteries, they also clearly and concisely recommend 
the appropriate work up and include recommendations for 
aggressive risk factor modiﬁ  cation, with lipid-lowering 
therapy, smoking cessation, walking programs, diet, and 
antiplatelet therapy (Figure 1). The ACC/AHA Guidelines 
for PAD is the source document for all practitioners who 
care for patients with PAD. 
Pathophysiology of atherothrombosis 
Atherosclerosis appears to be initiated as a result of 
endothelial injury and dysfunction. A cascade of events 
ensues over the course of months to years as inﬂ  ammatory 
cells, oxidized LDL, and smooth muscle cells form the 
true atherosclerotic plaque (Hirsch et al 1996; Fuster et al 
2005). The vulnerability of an atherosclerotic plaque has 
been the subject of intense research. Therapies to decrease 
potential plaque rupture have had a tremendous impact 
on clinical outcomes. However, ruptured atherosclerotic 
plaques continue to cause more morbidity and mortality 
throughout the world than any other disease. Antiplatelet 
therapy has been shown to decrease events as the platelet 
plays a pivotal role in atherothrombosis (CAPRIE 1996; 
Clopidogrel Trial 2001; ATC 2002; Vorchheimer and 
Becker 2006). Platelet adhesion, activation, and ultimately 
aggregation occur immediately following disruption of the 
endothelium. Platelet adhesion occurs through binding of 
von Willebrand’s factor and glycoprotein (GP) receptors, 
along with receptors for ﬁ  bronectin and collagen. Platelet 
adhesion leads to activation of the platelet with the liberation 
of a variety of cytoplasmic granules including adenosine 
diphosphate (ADP), thromboxane A2 (TXA2), collagen, 
serotonin, epinephrine, and thrombin (Figure 2). Platelet 
adhesion is highly enhanced by the release of these substances. 
The platelet is then further stimulated to release more of 
these substances as well as to conformationally change and 
express GP IIB/IIIA receptors. GP IIB/IIIA receptors bind 
ﬁ  brinogen connecting together millions of platelets forming 
the platelet plug, the core of an arterial thrombus (Lopez 
and Murray 1998). Thienopyridines are ADP receptor 
antagonists which irreversibly inhibit platelet activation. 
Ticlopidine was the ﬁ  rst-generation thienopyridine that was 
essentially replaced by clopidogrel (Figure 3). Clopidogrel 
has been tested in thousands of patients and is effective at 
decreasing platelet activation and subsequent risk of an 
atherothrombotic event (Figure 4). 
Diagnosis of PAD
Diagnosing PAD is straightforward when patients present with 
complaints or overt manifestations of an atherothrombotic 
event. In the asymptomatic patient, a thorough history and 
review of symptoms, inquiring particularly about exertional 
symptoms in the upper or lower extremities, is important 
in diagnosing PAD. The classic symptoms of intermittent 
claudication are exertional pain or cramping in the legs, 
brought on by the same degree of exertion and relieved 
with rest. Recently, more atypical features of claudication 
have been described and include lower extremity heaviness, 
generalized pain, or fatigue (McDermott et al 2001). The 
presence of symptoms assists in classifying the patient with 
lower extremity PAD (Table 1) (Dormandy and Rutherford 
2003). A review of risk factors for developing PAD (previous 
or current tobacco use, diabetes mellitus, hypertension, 
obesity, and dyslipidemia) is also important when diagnosing 
patients. Diabetic patients are at the highest risk of progression 
of disease and need for limb-saving surgery. The importance 
of diagnosis and treatment of PAD cannot be highlighted 
any more than by noting the fact that in patients with symp-
tomatic PAD, the relative risk of death from cardiac causes 
is increased almost six-fold (Criqui et al 1992). Diagnosis 
of PAD is best aided by a comprehensive physical examina-
tion. ACC/AHA guidelines give a Class I recommendation 
for a comprehensive pulse examination for patients at risk 
for lower extremity PAD (Hirsch et al 2006). Blood pres-
sure measurements in both arms should be performed on all Vascular Health and Risk Management 2007:3(3)  291
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Figure 1 ACC/AHA Guidelines for Cardiovascular Risk Reduction in Patients with peripheral arterial disease. Reproduced from Hirsch AT, Haskal ZJ, Hertzer, HR, et al. 2006. 
ACC/AHA Guidelines for the Management of Patients with Peripheral Artery Disease: Executive Summary. J Am Coll Cardiol, 47:1239–312. Copyright © 2006 with permission 
from Elsevier. 
ACC/AHA Guidelines: Cardiovascular Risk Reduction Recommendations 
A. Lipid-lowering drugs
Class I 1. Treatment with a hydroxymethyl glutaryl coenzyme-A reductase inhibitor (statin) medication is indicated for all patients with 
PAD to achieve a target low-density lipoprotein (LDL) cholesterol level of less than 100 mg per dl. (Level of Evidence: B) 
Class IIa 1. Treatment with a hydroxymethyl glutaryl coenzyme-A reductase inhibitor (statin) medication to achieve a target LDL choles-
terol level of less than 70 mg per dl is reasonable for patients with lower extremity PAD at very high risk of ischemic events. (Level of Evi-
dence: B) 2. Treatment with a ﬁ  bric acid derivative can be useful for patients with PAD and low high-density lipoprotein (HDL) cholesterol, 
normal LDL cholesterol, and elevated triglycerides. (Level of Evidence: C) 
B. Antihypertensive drugs
Class I 1. Antihypertensive therapy should be administered to hypertensive patients with lower extremity PAD to achieve a goal of less 
than 140 mm Hg systolic over 90 mm Hg diastolic (nondiabetics) or less than 130 mm Hg systolic over 80 mm Hg diastolic (diabetics 
and individuals with chronic renal disease) to reduce the risk of MI, stroke, congestive heart failure, and cardiovascular death. (Level of 
Evidence: A) 2. Beta-adrenergic blocking drugs are effective antihypertensive agents and are not contraindicated in patients with PAD. 
(Level of Evidence: A) 
Class IIa 1 The use of ACE inhibitors is reasonable for symptomatic patients with lower extremity PAD to reduce the risk of adverse 
cardiovascular events. (Level of Evidence: B) 
Class IIb 1 Angiotensin-converting enzyme inhibitors may be considered for patients with asymptomatic lower extremity PAD to reduce 
the risk of adverse cardiovascular events. (Level of Evidence: C) 
C. Diabetes therapies
Class I 1 Proper foot care, including use of appropriate footwear, chiropody/podiatric medicine, daily foot inspection, skin cleansing, and 
use of topical moisturizing creams should be encouraged, and skin lesions and ulcerations should be addressed urgently in all diabetic 
patients with lower extremity PAD. (Level of Evidence: B) 
Class IIa 1. Treatment of diabetes in individuals with lower extremity PAD by administration of glucose control therapies to reduce 
the hemoglobin A1C to less than 7% can be effective to reduce microvascular complications and potentially improve cardiovascular 
outcomes. (Level of Evidence: C) 
D. Smoking cessation
Class I 1. Individuals with lower extremity PAD who smoke cigarettes or use other forms of tobacco should be advised by each of 
their clinicians to stop smoking and should be offered comprehensive smoking cessation interventions, including behavior modiﬁ  cation 
therapy, nicotine replacement therapy, or bupropion. (Level of Evidence: B) 
E. Homocysteine-lowering drugs
Class IIb 1 The effectiveness of the therapeutic use of folic acid and B12 vitamin supplements in individuals with lower extremity PAD 
and homocysteine levels greater than 14 micromoles per liter is not well established. (Level of Evidence: C) 
F. Antiplatelet and antithrombotic drugs
Class I 1. Antiplatelet therapy is indicated to reduce the risk of MI, stroke, or vascular death in individuals with atherosclerotic lower 
extremity PAD. (Level of Evidence: A) 2. Aspirin, in daily doses of 75 to 325 mg, is recommended as safe and effective antiplatelet therapy to 
reduce the risk of MI, stroke, or vascular death in individuals with atherosclerotic lower extremity PAD. (Level of Evidence: A) 3. Clopi-
dogrel (75 mg per day) is recommended as an effective alternative antiplatelet therapy to aspirin to reduce the risk of MI, stroke, or 
vascular death in individuals with atherosclerotic lower extremity PAD. (Level of Evidence: B) 
Class III 1 Oral anticoagulation therapy with warfarin is not indicated to reduce the risk of adverse cardiovascular ischemic events in 
individuals with atherosclerotic lower extremity PAD. (Level of Evidence: C) 
patients suspected of having PAD. Left subclavian artery 
stenosis is under diagnosed and often asymptomatic until the 
patient develops a severe high grade stenosis. Auscultation 
for bruits in the neck, supraclavicular area, abdomen, ﬂ  ank, 
and groins must be done as well. In addition to a thorough 
history and physical examination, the ankle brachial index 
is a powerful, yet simple ofﬁ  ce-based tool to diagnose and 
determine the severity of lower extremity PAD. Moreover, it 
is highly accurate in predicting the associated risk of future 
cardiovascular events such as fatal myocardial infarction 
(MI), stroke (CVA), and vascular deaths (Sikkink et al 1997). 
The Ankle Brachial-Index measurement (ABI) can be easily 
performed in an ofﬁ  ce setting with the use of Doppler, gel, 
and a sphygmomanometer (Hiatt 2001). A normal ABI is 
between 0.9 and 1.2. An ABI less than 0.90 is 99% speciﬁ  c 
and 95% sensitive for the diagnosis of PAD (McDermott 
et al 2002). An ABI less than 0.9 but above 0.6 is representa-
tive of mild to moderate disease. ABIs of 0.4 to 0.6 will result Vascular Health and Risk Management 2007:3(3)  292
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in severe claudication symptoms. Lower ABIs correlate 
with even more severe disease as rest pain and critical 
ischemia can be reﬂ  ected in ABIs of 0.25 to 0.4. If PAD 
is suspected but the resting ABI is normal, exercise ABIs 
should be performed. Pulse volume recordings, segmental 
limb arterial blood pressures and Doppler waveforms also 
can be performed to provide further information regard-
ing arterial disease. When revascularization is imminent, 
duplex ultrasonography, MR, and CT angiography can be 
obtained to map arterial disease anatomically. Conventional 
angiography is not indicated in patients with claudication 
symptoms and normal exercise ABIs (Hirsch et al 2006). 
Diagnosis via conventional angiography should be reserved 
for patients presenting with acute or critical limb ischemia 
at risk for limb loss and in need of urgent revascularization 
(Hirsch et al 2006).
Management of PAD
The primary goal in treating patients with PAD is two fold: 
the prevention of future cardiovascular events in addition to 
maximal secondary preventive measures using antiplatelet 
therapy and smoking cessation, and treating hypertension, 
hyperlipidemia, and diabetes mellitus. These steps will 
lower the risk of future atherothrombotic events as these 
patients have a signiﬁ  cant increased risk of events (Figure 5). 
Adhering to a daily regimen of exercise and modifying the 
dietary intake of fat must be included in this therapeutic plan. 
The ACC/AHA practice guidelines (Figure 1) give a Class 
I indication for the use of statins to treat LDL to a goal of 
less than 100 mg/dL with less than 70 mg/dL as a therapeutic 
option in the very high risk patients (Hirsch et al 2006). 
Hypertensive patients should be treated aggressively to 
achieve a systolic less than 130 mmHg and a diastolic less 
than 80 mmHg. Weight reduction, dietary restrictions and 
complete tobacco cessation are necessary as well. 
Antiplatelet therapy has been shown in multiple studies 
and meta-analyses to prevent the risk of occlusive arte-
rial disease in patients with PAD (ATC 2002). The most 
widely used antiplatelet agent is aspirin, which has been 
used for centuries. Aspirin blocks platelet activation by 
Table 1 Classiﬁ  caton of peripheral arterial disease
 Fontaine    Rutherford
Stage Clinical  Grade  Category  Clinical
1 Asymptomatic  0  0 Asymptomatic
IIa  Mild claudication  I  1  Mild claudication
IIb  Moderate-severe claudication  I  2  Moderate claudication
   I  3  severe  claudication
III  Ischemic rest pain  II  4  Ischemic rest pain
IV  Ulceration or gangrene  III  5  Minor tissue loss
    IV  6  Ulceration or gangrene
Reproduced from Dormandy JA, Rutherford RB. 2000. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic InterSociety Consensus 
(TASC). J Vasc Surg, 31:S1-S296. Copyright © 2000 with permission from Elsevier.
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Figure 2 Platelet interactions with diseased endothelium. Endothelial dysfunction, a consequence of a variety of disease states, has important implications for platelet ag-
gregation and vascular tone. When platelets aggregate, they release thromboxane A2 (TxA2), 5-hydroxytryptamine (5-HT, or serotonin), and ADP. Vascular Health and Risk Management 2007:3(3)  293
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irreversibly inhibiting cyclo-oxygenase; this reduces the 
production of the potent prothrombotic and vasoconstric-
tive agent, thromboxane A2. To date, the largest meta-
analysis studying the use of aspirin was conducted by the 
Antithrombotic Trialists’ Collaboration, which showed 
marked reduction in vascular events in patients treated 
with aspirin (ATC 2002). This meta-analysis combined 
data from 287 studies with over 13,500 high-risk patients 
with cardiovascular disease and compared the efﬁ  cacy of 
anti-platelet therapy against control. The use of anti-platelet 
agents aspirin and ticlopidine resulted in a 22% reduction 
in adverse cardiovascular events deﬁ  ned as MI, CVA, or 
vascular death (ATC 2002). Of the 287 studies, 42 were 
randomized reports of nearly 10,000 patients with PAD. 
The use of aspirin in this subset of patients resulted in a 
signiﬁ  cant 23% decrease in the incidence of non-fatal MI 
or CVA and fatal vascular death (ATC 2002). 
Clopidogrel, a thienopyridine derivative that inhibits 
platelet aggregation, has been widely studied in the treat-
ment of patients at risk for cardiovascular events (Figure 4). 
It inhibits platelet aggregation by selectively inhibiting the 
binding of the adenosine 5’-diphosphate molecule to the 
P2Y12 receptor on the platelet surface (Mills et al 1992). This 
property of clopidogrel leads to inhibition of platelet activa-
tion and aggregation, thereby making it an important agent 
in the prevention of thrombotic complications especially in 
acute vascular ischemic events. The use of clopidogrel was 
studied in the CAPRIE (Clopidogrel versus Aspirin in Patients 
at Risk for Ischemic Events) trial, a randomized double blind 
controlled study of almost 20,000 patients, nearly 6000 with 
PAD (CAPRIE 1996). This randomized trial compared 
clopidogrel 75 mg daily with aspirin 325 mg daily with the 
primary endpoint of vascular death, non-fatal myocardial 
infarction, or CVA. At 1.9-year follow-up, the incidence of 
primary endpoint was 3.7% in the clopidogrel arm versus 
4.9% in the aspirin arm, equating to a signiﬁ  cant 24% rela-
tive risk reduction (CAPRIE 1996). Clopidogrel treatment 
in patients with symptomatic PAD was more effective than 
aspirin in preventing ischemic events (CAPRIE 1996).
Much focus has been given to the use of dual anti-platelet 
therapy in the prevention of ischemic events in generally 
high-risk patients. As mentioned, clopidogrel and aspirin 
work by different mechanisms to irreversibly block plate-
let activation. Hypothetically, the combination of aspirin 
and clopidogrel should yield an even stronger antiplatelet 
effect producing even more protection against thrombotic 
complications of acute ischemic events. The combination 
of aspirin and clopidogrel therapy versus aspirin alone 
was recently reported in the CHARISMA (Clopidogrel 
and Aspirin versus Aspirin Alone for the Prevention of 
Atherothrombotic Events) trial, a multicenter, randomized 
placebo-controlled, double blind trial of over 15,000 patients 
(Bhatt et al 2006). The study looked at a broad group of 
patients, with a large percentage at lower risk for athero-
thrombotic events who did not have established cardiovas-
cular disease. Additionally, this study included a high risk 
subgroup with established cardiovascular disease and nearly 
3000 patients with known PAD. Overall, no beneﬁ  t was seen 
when clopidogrel was added to aspirin versus aspirin alone 
in reducing the primary efﬁ  cacy endpoint of MI, CVA, or 
vascular death in the overall population of patients (Bhatt 
et al 2006). However, the study period was relatively short 
with a follow up of only 30 months, which could account for 
the lack of beneﬁ  t seen in a population of largely low-risk 
patients. Conversely, the higher-risk subgroup of patients 
with established cardiovascular disease appeared to derive 
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a beneﬁ  t from the combination of aspirin and clopidogrel. 
Also, the suggestion of increased harm in the low-risk group 
was made. The question of whether dual antiplatelet is for all 
patients at risk for atherothrombosis has likely been answered 
in the CHARISMA. Patients with established and diffuse 
atherosclerosis, particularly with PAD, remain at the highest 
risk for atherothrombosis and should strongly be considered 
candidates for dual antiplatelet therapy with 81 mg of aspirin 
and 75 mg of clopidogrel (Bhatt et al 2006).
The secondary goal in the management of PAD involves 
the treatment of lifestyle and the limitation of symptoms in 
order to improve quality of life. PAD patients with intermit-
tent claudication account for the largest group of symptomatic 
patients. Exercise therapy is recommended for all patients 
with claudication symptoms. A supervised exercise training 
program that is monitored by trained personnel has been 
studied in numerous trials. Increase in walking abilities has 
been shown in large meta-analyses from the Cochrane 
Collaboration (Leng et al 2000). Drug therapy with cilostazol 
is indicated to improve walking time and reduce painful lower 
extremity claudication. Although the true mechanism of its 
action is unknown, cilostozol has numerous actions including 
anti-platelet activity, a vasodilatory effect, and improve-
ment in HDL levels (Igawa et al 1990). Use of this agent is 
limited by its side-effects of headache, nausea, palpitations, 
and dizziness. Due to its inhibition of phosphodiesterase 
III, the FDA has a black-box warning for use of cilostazol 
in patients with heart failure and left ventricular dysfunction 
(Hirsch et al 2006). Trental, a rheolytic agent with effects on 
platelet aggregation, can be considered as a second alterna-
tive to cilostazol. Due to its unpredictable effectiveness, the 
ACC/AHA practice guidelines give it a Class IIb indication 
(Hirsch et al 2006).
Revascularization via surgery or endovascular procedures 
is reserved for patients that have lifestyle-altering disabilities 
due to the severity of PAD or intermittent claudication. 
Although a detailed review of revascularization procedures is 
beyond the scope of this article, numerous methods to include 
percutaneous transluminal angioplasty (PTA) with balloon 
dilation, atherectomy and stents have been implemented 
successfully in the treatment of claudication. These proce-
dures, including surgical revascularization, can effectively 
decrease or entirely alleviate the symptoms of PAD. The 
majority of patients who are treated with either surgical or 
endovascular revascularization should be treated with aspirin 
and clopidogrel for at least a month following the procedure 
and, often, indeﬁ  nitely.
Complications of PAD
MI and CVA remain the most serious complications as-
socoiated with PAD. Other complications are related to the 
area of the body supplied by the artery involved. Whether 
it is mesenteric ischemia, renovascular hypertension, or 
intermittent claudication, the end result of untreated severe 
arterial stenoses is progression to possible occlusion of the 
artery and infarction of the tissue it supplies.
 Lower extremity critical limb ischemia, occurring when 
limb perfusion becomes critically low to the point that limb 
tissue viability is jeopardized, can lead to tissue loss and 
gangrene. Acute limb ischemia is a severe complication of 
PAD due to arterial embolism or acute arterial thrombosis. 
The classic hallmark signs of acute critical limb ischemia in-
clude the 5 “Ps”: pain, pulselessness, palor, paresthesias, and 
paralysis. Suggestions to add a 6th “P”, polar, describing the 
coolness of the affected extremity have been made (Hirsch 
et al 2006). Acute treatment consists of re-establishing ﬂ  ow 
to peripheral tissue beds by recanalizing the occluded artery. 
This can be performed with either catheter-based thromboly-
sis or mechanical thrombectomy or surgical thrombectomy 
or bypass. In the worst case, primary amputation should be 
considered when vast areas of necrosis are already encoun-
tered in the late presentation of critical limb ischemia. One-
year mortality rates are greater than 20% for patients with 
chronic limb ischemia (Dormandy and Rutherford 2000). 
Furthermore, morbidity is even higher, approaching 40% 
for those patients who have disease that is not amenable to 
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Figure 5 Risk of developing lower extremity peripheral arterial disease. The range 
for each risk factor is estimated from epidemiologic studies (see text). The relative 
risks take into consideration current smokers vs. former smokers and nonsmokers; 
the presence vs the absence of diabetes and hypertension; and the highest vs. the 
lowest quartile of homocysteine and C-reactive protein. The estimate for hyper-
cholesterolemia is based on a 10% risk for each 10 mg/dL rise in total cholesterol. 
Adapted from Dormandy JA, Rutherford RB. 2000. Management of peripheral 
arterial disease (PAD). TASC Working Group. TransAtlantic InterSociety Consensus 
(TASC). J Vasc Surg, 31:S1-S296. Copyright © 2000 with permission from Elsevier. Vascular Health and Risk Management 2007:3(3)  295
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peripheral or surgical intervention and will eventually require 
limb amputation. Therefore, the treatment and prevention of 
progression of PAD is critically important. All measures to 
control the progression of atherosclerosis, decrease modiﬁ  -
able risk factors, and treat the hyperactive platelet state, 
needless to say, should be aggressively implemented. The
development and rupture of abdominal aortic aneurysms 
(AAA) is a catastrophic complication. Screening measures 
and early treatment are outlined in the ACC/AHA guidelines 
(Hirsch et al 2006). Atherosclerotic renal artery stenosis 
causes renal insufﬁ  ciency and uncontrolled hypertension. 
This can be effectively treated with renal artery stenting. 
Subclavian steal from severe stenosis in the subclavian or 
innominate arteries can cause vertebrobasilar insufﬁ  ciency 
with patients who present with dizziness, syncope, and 
vertigo; these patients can also have claudication of the 
upper extremity. If the stenosis is distal to the left vertebral 
artery, the patient will present only with left arm claudica-
tion. Signiﬁ  cant disease in the innominate artery can also 
lead to subclavian steal syndrome with often very dramatic 
symptoms if reversal of ﬂ  ow occurs in the right vertebral 
and carotid arteries. The coronary-subclavian steal syndrome 
occurs in patients with severe left subclavian stenosis caus-
ing reversal of ﬂ  ow in the left internal mammary graft to 
the left anterior descending coronary artery (LAD). These 
patients often present with angina, particularly if they are 
using their left arm. 
Safety and tolerability
Millions of prescriptions have been written for clopidogrel 
over the past few years. Clopidogrel was the third most pre-
scribed medication by US cardiologists in 2005. The most 
experience with clopidogrel comes from the patients who 
undergo coronary artery stent implantation and subsequent 
treatment with clopidogrel. These patients are treated with the 
combination of clopidogrel 75 mg daily along with aspirin 
325 mg for 1 month, following bare metal stent implantation, 
3 months with sirolimus-eluting stents and 6 months with 
paclitaxel-eluting stents. Many interventional cardiologists 
treat patients with aspirin and clopidogrel for up to a year 
and often indeﬁ  nitely when drug eluting stents are placed. 
Patients discharged after admission for acute coronary 
syndromes are generally treated for at least a year with the 
aspirin and clopidogrel combination (Smith et al 2006). 
Patients with peripheral artery disease and carotid artery 
stent implantation constitute a smaller population of patients 
in whom the aspirin and clopidogrel combination is being 
used. The most data accumulated recently have involved 
the CHARISMA, COMMIT (ClOpidogrel and Metoprolol 
in Myocardial Infarction Trial), and CLARITY-TIMI 28 
(Addition of clopidogrel to aspirin and ﬁ  brinolytic therapy 
for myocardial infarction with ST-segment elevation) trials 
where major safety endpoints were not statistically different 
in comparing aspirin and clopidogrel with aspirin alone (Chen 
et al 2005; Sabatine et al 2005; Bhatt et al 2006).
The most common side-effect seen in patients taking 
clopidogrel has been a hypersensitivity drug eruption. 
The onset can occur days to weeks after the initiation of 
the medication and generally requires discontinuation of 
clopidogrel. Acute treatment involves antihistamines, and 
sometimes steroids are needed. The cessation of the drug 
and replacement with ticlopidine is often required. Rarely, 
patients can be treated through their drug eruption or they 
can undergo clopidogrel desensitization, which has been 
shown to be safe and successful in a number of case series 
(Camara and Almeda 2006).
The least likely side-effect to occur with clopidogrel 
use is thrombotic thrombocytopenic purpura (TTP). TTP 
has been reported by Bennett et al (2000) as a serious life-
threatening complication of taking clopidogrel. The incidence 
of clopidogrel associated TTP is felt to be less than 4 cases 
per 1 million (Bristol-Myers Squibb and Sanoﬁ  -Synthelabo 
2002). However, it has been argued that these patients may 
develop TTP coincidentally with recent initiation of clopi-
dogrel and that no causal relationship exists at all (Majhail 
and Lichtin 2003).
Serious bleeding from clopidogrel is certainly a con-
cern but is likely related to concomitant use with other 
anti-platelet and antithrombotic medications. Dual or triple 
antiplatelet therapy or antiplatelet therapy combined with 
antithrombotic therapy increases the likelihood of major and 
minor bleeding. Khurram et al (2006) reported the combined 
use of aspirin, clopidogrel, and warfarin had a signiﬁ  cantly 
increased risk of bleeding compared with the dual antiplatelet 
group of aspirin and clopidogrel. Major bleeding was 6.6% 
in the triple therapy group versus 0% in the dual antiplatelet 
group; minor bleeding was 14.9% versus 3.8%, respectively 
(Khurram et al 2006). In the PAD population studied in 
CAPRIE, the incidence of bleeding with clopidogrel versus 
aspirin was not statistically different (CAPRIE 1996). In 
CURE, however, the risk of both major and minor bleeding 
was signiﬁ  cantly higher with the combination of aspirin and 
clopidogrel versus aspirin alone (Clopidogrel Trial 2001). 
Although as the dose of the aspirin given increased, the risk 
of major and minor bleed increased equally in both arms 
(Clopidogrel Trial 2001). Vascular Health and Risk Management 2007:3(3)  296
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Hemorrhagic complications are increased with all 
antiplatelet and antithrombotic medications. Gastrointestinal 
erosions and bleeding with aspirin are well recognized 
phenomena. Clopidogrel does not appear to induce lesions 
and cause bleeding but likely increases the risk of some 
underlying pathology to be more prone to bleed. Another 
theory is clopidogrel impairs the long-term healing of patients 
with prior gastrointestinal ulcers. A 2005 study by Chan 
et al (2005) found patients with recent gastrointestinal 
(GI) bleeding, aspirin, and esomeprazole was better than 
clopidogrel alone for recurrent GI bleeding. This report 
had a number of ﬂ  aws and was criticized as a small study 
without an arm looking at esomeprazole and clopidogrel. In 
CAPRIE, with patients receiving clopidogrel, GI hemorrhage 
occurred at a rate of 2.0%, and hospitalization was required 
in 0.7% (CAPRIE 1996). In patients receiving aspirin, the 
corresponding rates were 2.7% and 1.1%, respectively 
(CAPRIE 1996). In CURE, the Clopidogrel in Unstable 
Angina to Prevent Recurrent Events Trial, the incidence of 
major GI bleeding was 1.3% vs 0.7% (Clopidogrel + aspirin 
vs placebo + aspirin, respectively) (Clopidogrel Trial 2001). 
Clopidogrel should be used with caution in patients who are 
at risk for bleeding, have had peptic ulcer disease, NSAID 
induced gastritis or bleed and those patients chronically 
taking NSAIDS. Proton pump inhibitors should be used 
concomitantly to reduce the risk of GI bleed. Patients with 
hepatic or renal impairment are at potentially higher risk of 
hemorrhagic complications with clopidogrel. Use in these 
patients is limited and close monitoring and patient education 
regarding increased risk is necessary. 
Intracranial and other life-threatening bleeding is uncom-
mon. The incidence of intracranial hemorrhage is 0.4% for 
clopidogrel compared with 0.5% for aspirin. Surgical bleed-
ing is increased if patients do not stop taking clopidogrel at 
least 5 days prior to the surgery. Current recommendations 
are to hold clopidogrel at least 5 to 7 days prior to any 
surgery.
Patient perspectives
Patient complaints of easy bruising are frequent with most 
antiplatelet or antithrombotic medications. The combination 
of aspirin and clopidogrel increases those complaints. In the 
triple therapy, patients in whom warfarin is also needed, the 
risk of hemorrhagic complications is signiﬁ  cant, requiring 
meticulous attention to the international normalized ratio, 
maintaining it at its lowest possible threshold and using the 
lowest possible dose of aspirin. Measuring platelet aggregation 
and thromboelastography may be quite beneﬁ  cial in managing 
these patients. Other than easy bruising and a small incidence 
of drug eruptions with initiation of therapy, clopidogrel is 
very well tolerated and effective at reducing atherothrom-
botic risk. Patient satisfaction is generally very good as is 
adherence.
Conclusion
Antiplatelet therapy in some form is required in all patients 
with vascular disease. Clopidogrel in patients with PAD 
is a critically important therapy, particularly in the higher 
risk patients. Clopidogrel carries the only FDA-labeled 
indication for cardiovascular risk reduction in patients with 
established PAD. Those patients with diffuse, severe ath-
erosclerosis, or those who have had multiple atherothrom-
botic events, are at the highest risk for recurrent events; 
dual antiplatelet therapy is likely beneﬁ  cial in this group 
of patients. Combination therapy is also recommended in 
patients who have had an event on aspirin as they likely 
need more platelet inhibition. Risk reduction with aspirin 
is far less expensive but slightly less effective as seen in 
CAPRIE (CAPRIE 1996). The combination of aspirin and 
clopidogrel may increase the possibility of bleeding in lower 
risk patients, however, in higher risk patients, the beneﬁ  ts 
likely outweigh the risk (Bhatt et al 1006). The CHARISMA 
trial did not show a beneﬁ  t in the total population studied 
(Bhatt et al 1006). However, if a greater portion of patients 
studied were the highest risk patients and followed for a 
longer duration of time, there might have been a signiﬁ  cant 
beneﬁ  t of the combination of aspirin and clopidogrel versus 
aspirin alone. 
Antiplatelet therapy, particularly with clopidogrel, is a 
mainstay of therapy to prevent atherothrombotic events in 
high risk patients. Aggressive risk reduction with the addi-
tion of clopidogrel is mandatory for patients who experience 
atherothrombotic events while already receiving aspirin, 
for patients who are aspirin intolerant and for patients with 
established cardiovascular disease in multiple vascular beds. 
Additionally, patients with a history of atherothrombosis 
who still smoke, or patients who are statin intolerant or 
whose cholesterol cannot be optimally reduced, are also 
ideal candidates for more aggressive antiplatelet therapy 
with clopidogrel and/or the combination of clopidogrel and 
low-dose aspirin in order to reduce their risk for future ath-
erothrombotic events.
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